Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
TRC105 is a human/murine chimeric IgG1 antibody administered i.v. every two weeks (on days 1 and 15) or weekly (on days 1, 8, 15 and 22) of each 28 day cycle; until progression or unacceptable toxicity develops.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
The patient has given informed consent.
The patient is willing and able to abide by the protocol.
The patient has cancer and curative therapy is unavailable.
The patient is at least 18 years old.
The patient has adequate ability to perform activities of daily living.
Significant toxicities from prior therapy must have recovered.
The patient has adequate organ function as assessed by laboratory test.
The patient weighs more than 264 lbs.
The patient has a known allergy to gentamicin
The patient has had prior treatment with high-dose chemotherapy requiring stem cell rescue
The patient is currently on treatment on another therapeutic clinical trial or has received an investigational agent within 4 weeks prior to first dose with study drug
The patient has had prior surgery (including open biopsy), radiation therapy or systemic therapy within 4 weeks of starting the study treatment
The patient has hypertension > 160/90
The patient has a history of CNS cancer
The patient has an unstable medical condition including, but not limited to, cardiac disease, history of stroke, active hepatitis, or significant pericardial, pleural or peritoneal effusion
The patient received recent thrombolytic or anticoagulant therapy
The patient has lung cancer with central chest lesions
The patient has had hemorrhage or unhealed wounds within 30 days of dosing
The patient has used systemic corticosteroids within 3 months of dosing
The patient has known HIV/AIDS
The patient has a history of hypersensitivity reaction to human or mouse antibody products
The patient is pregnant or breastfeeding.
The patient has a history of peptic ulcer disease or gastritis within 6 months of dosing, unless complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 30 days of dosing